Mergers & Acquisitions ·
Sangamo Therapeutics, Inc., which operates in the biotechnology industry developing gene therapies, filed a voluntary…
SGMOSangamo Therapeutics, Inc
Sangamo Therapeutics, Inc., which operates in the biotechnology industry developing gene therapies, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026. On August 25, 2026, the Company entered into an Asset Purchase Agreement with PTC Therapeutics, Inc., to sell assets primarily related to ST-920, a gene therapy candidate for Fabry disease. The transaction includes $111 million in cash consideration and up to $100 million in contingent milestone payments upon FDA approval of a biologics license application. The deal is subject to Bankruptcy Court approval, with a hearing scheduled for September 10, 2026.